Financial Ratios Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.100 USD | +2.20% | +1.59% | +20.85% |
07-31 | Transcript : Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024 | |
07-31 | Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.49 | 3.35 | 4.68 | 0.64 | -1.36 | |||||
Return on Total Capital | 4.07 | 3.82 | 5.36 | 0.75 | -1.6 | |||||
Return On Equity % | 33.67 | 5.4 | 6.92 | 1.22 | 0.47 | |||||
Return on Common Equity | 33.67 | 5.4 | 6.92 | 1.22 | 0.47 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 89.22 | 90.59 | 90.46 | 90.45 | 92.32 | |||||
SG&A Margin | 57.11 | 56.62 | 46.17 | 53.65 | 58.6 | |||||
EBITDA Margin % | 11.31 | 12.13 | 16.75 | 3.56 | -5.68 | |||||
EBITA Margin % | 10.7 | 11.57 | 16.24 | 3.08 | -6.16 | |||||
EBIT Margin % | 10.04 | 10.98 | 15.69 | 2.49 | -7.24 | |||||
Income From Continuing Operations Margin % | 50.86 | 9.4 | 12.34 | 2.47 | 1.3 | |||||
Net Income Margin % | 50.86 | 9.4 | 12.34 | 2.47 | 1.3 | |||||
Net Avail. For Common Margin % | 50.86 | 9.4 | 12.34 | 2.47 | 1.3 | |||||
Normalized Net Income Margin | 7.99 | 7.97 | 9.85 | 2.78 | -0.8 | |||||
Levered Free Cash Flow Margin | 14.83 | 15.52 | 17.95 | 12.71 | -46.08 | |||||
Unlevered Free Cash Flow Margin | 14.83 | 15.52 | 17.95 | 12.71 | -46.08 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.56 | 0.49 | 0.48 | 0.41 | 0.3 | |||||
Fixed Assets Turnover | 23.35 | 16.75 | 19.92 | 21.78 | 19.16 | |||||
Receivables Turnover (Average Receivables) | 8.24 | 8.8 | 8.6 | 7.71 | 5.69 | |||||
Inventory Turnover (Average Inventory) | 22.95 | 19.31 | 22.24 | 21.89 | 11.6 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.95 | 6.21 | 6.43 | 5.68 | 4.94 | |||||
Quick Ratio | 5.69 | 6.03 | 6.25 | 5.47 | 4.82 | |||||
Operating Cash Flow to Current Liabilities | 0.77 | 0.79 | 0.86 | 0.35 | 0.15 | |||||
Days Sales Outstanding (Average Receivables) | 44.3 | 41.59 | 42.45 | 47.33 | 64.1 | |||||
Days Outstanding Inventory (Average Inventory) | 15.9 | 18.95 | 16.41 | 16.68 | 31.46 | |||||
Average Days Payable Outstanding | 23.74 | 21.19 | 14.2 | 101.62 | 241.99 | |||||
Cash Conversion Cycle (Average Days) | 36.46 | 39.35 | 44.67 | -37.61 | -146.42 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 3.55 | 3 | 2.45 | 2.11 | 1.73 | |||||
Total Debt / Total Capital | 3.43 | 2.92 | 2.39 | 2.07 | 1.7 | |||||
LT Debt/Equity | 3.03 | 2.54 | 1.99 | 1.67 | 1.29 | |||||
Long-Term Debt / Total Capital | 2.93 | 2.46 | 1.94 | 1.64 | 1.26 | |||||
Total Liabilities / Total Assets | 15.05 | 15.03 | 14.97 | 16.88 | 15.97 | |||||
Total Debt / EBITDA | 0.51 | 0.42 | 0.26 | 0.96 | -1.13 | |||||
Net Debt / EBITDA | -10.48 | -10.8 | -8.81 | -39.08 | 45.42 | |||||
Total Debt / (EBITDA - Capex) | 0.53 | 0.44 | 0.26 | 1.01 | -0.09 | |||||
Net Debt / (EBITDA - Capex) | -10.87 | -11.42 | -8.92 | -41.49 | 3.46 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 17.64 | 9.23 | 8.27 | -5.32 | -24.27 | |||||
Gross Profit, 1 Yr. Growth % | 17.43 | 10.9 | 8.12 | -5.33 | -22.71 | |||||
EBITDA, 1 Yr. Growth % | 4.08 | 17.12 | 49.51 | -79.86 | -220.75 | |||||
EBITA, 1 Yr. Growth % | 4.51 | 18.1 | 51.98 | -82.02 | -251.2 | |||||
EBIT, 1 Yr. Growth % | 4.93 | 19.42 | 54.8 | -84.99 | -320.45 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 358.4 | -79.8 | 42.06 | -81.07 | -60.02 | |||||
Net Income, 1 Yr. Growth % | 358.4 | -79.8 | 42.06 | -81.07 | -60.02 | |||||
Normalized Net Income, 1 Yr. Growth % | 14.53 | 9.05 | 33.83 | -73.33 | -129.51 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 339.58 | -80.09 | 38.1 | -81.03 | -63.64 | |||||
Accounts Receivable, 1 Yr. Growth % | -8.38 | 13.92 | 8.09 | 3.22 | 1.92 | |||||
Inventory, 1 Yr. Growth % | 14.69 | 12.28 | -19.92 | 16.49 | 13.65 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 240.59 | -2.98 | -15.14 | -11.4 | -16.7 | |||||
Total Assets, 1 Yr. Growth % | 45.65 | 10.28 | 11.31 | 6.81 | 2.24 | |||||
Tangible Book Value, 1 Yr. Growth % | 54.62 | 11.29 | 12.31 | 4.91 | -16.73 | |||||
Common Equity, 1 Yr. Growth % | 49.21 | 10.3 | 11.4 | 4.41 | 3.36 | |||||
Cash From Operations, 1 Yr. Growth % | 53.23 | 12.68 | 24.03 | -50.19 | -59.98 | |||||
Capital Expenditures, 1 Yr. Growth % |